Analystreport

Fate Therapeutics, Inc. (NASDAQ: FATE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.

Fate Therapeutics, Inc.  (FATE) 
Last fate therapeutics, inc. earnings: 3/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.fatetherapeutics.com/investor-relations